Ebola virus altered innate and adaptive immune response signalling pathways: Implications for novel therapeutic approaches

Infectious Disorders - Drug Targets

Volumn 16, Issue 2, 2016, Pages 79-94

  Kumar, Anoop ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

B cell; Ebola virus; Immune system; T cell; TLRs; Vaccine; VP35

Indexed keywords

3 DEAZANEPLANOCIN A; C REACTIVE PROTEIN; EBOLA VACCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; KIDNEY INJURY MOLECULE 1; MANNOSE BINDING LECTIN; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS PROTEIN VP24; VIRUS PROTEIN VP35; ANTIVIRUS AGENT;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DRUG TARGETING; EBOLA HEMORRHAGIC FEVER; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); VIRUS ENTRY; AFRICA; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; AFRICA; ANIMALS; ANTIVIRAL AGENTS; DRUG DISCOVERY; EBOLA VACCINES; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNITY, INNATE; SIGNAL TRANSDUCTION;

EID: 84975784572     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/1871526516666160108114644     Document Type: Article

References (120)

1. Kawai, T.; Akira, S. The role of pattern recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol., 2010, 11, 373-384.
2. Takeuchi, O.; Akira, S. Innate immunity to virus infection. Immunol. Rev., 2009, 227, 75-86.
3. Zajac, A.J.; Harrington, L.E. Immune Response to Viruses: Cell-Mediated Immunity. Encycl Virol, Third Edition 2008, 3, 70-77.
4. Negredo, A.; Palacios, G.; Vazquez Moron, S.; Gonzalez, F.; Dopazo, H.; Molero, F.; Juste, J.; Quetglas, J.; Savji, N.; De la Cruz Martinez, M.; Herrera, J.E.; Pizarro, M.; Hutchison, S.K.; Echevarria, J.E.; Lipkin, W.I.; Tenorio, A. Discovery of an ebolavirus-like filovirus in europe. PLoS Pathogen, 2011, 7, e1002304.
5. Towner, J.S.; Pourrut, X.; Albarino, C.G.; Nkogue, C.N.; Bird, B.H.; Grar, G.; Ksiazek, T.G.; Gonzalez, J.P.; Nichol, S.T.; Leroy, E.M. Marburg virus infection detected in a common African bat. PLoS One, 2007, 2, e764.
6. Kuhn, J.H.; Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, Lipkin WI, Negredo AI, Netesov, S.V.; Nichol, S.T.; Palacios, G.; Peters, C.J.; Tenorio, A.; Volchkov, V.E.; Jahrling, P.B. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch. Virol., 2010, 155, 2083-2103.
7. Negredo, A.; Palacios, G.; Vazquez Moron, S.; Gonzalez, F.; Dopazo, H.; Molero, F.; Juste, J.; Quetglas, J.; Savji, N.; de la Cruz Martinez, M.; Herrera, J.E.; Pizarro, M.; Hutchison, S.K.; Echevarria, J.E.; Lipkin, W.I.; Tenorio, A. Discovery of an ebolavirus-like filovirus in europe. PLoS Pathogens, 2011, 7, e1002304.
8. Bray, M. Pathogenesis of viral hemorrhagic fever. Curr. Opinion Immunol., 2005, 17, 399-403.
9. Geisbert, T.W.; Hensley, L.E. Ebola virus: new insights into disease a etiopathology and possible therapeutic interventions. Exp. Rev. Mol. Med., 2004, 6, 1-24.
10. Feldmann, H.; Geisbert, T.W. Ebola haemorrhagic fever. Lancet, 2011, 377, 849-862.
11. Bowen, E.T.; Lloyd, G.; Harris, W.J.; Platt, G.S.; Baskerville, A.; Vella, E.E. Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological agent. Lancet., 1977, 1, 571-573.
12. Johnson, K.M.; Lange, J.V.; Webb, P.A.; Murphy, F.A. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet, 1977, 1, 569-571.
13. Peters, C.J.; Khan, A.S. Filovirus diseases. Curr. Top. Microbiol. Immunol., 1999, 235, 85-95.
14. Sanchez, A.; Khan, A.S.; Zaki, S.R.; Nabel, G.J.; Ksiazek, T.G.; Peters, C.J. Filoviridae: Marburg and Ebola viruses. In D. M. Knipe and P. M. Howley (ed.), Fields virology. Lippincott, Williams & Wilkins, Philadelphia, Pa. 2001, 1279-1304.
15. Zaki, S.R.; Goldsmith, C.S. Pathologic features of filovirus infections in humans. Curr. Top Microbiol Immunol., 1999, 235, 97-116.
16. Bwaka, M.A.; Bonnet, M.J.; Calain, P.; Colebunders, C.; Roo, A.D.; Guimard, Y.; Katwiki, K.R.; Kibadi, K.; Kipasa, M.A.; Kuvula, K.J.; Mapanda, B.B.; Massamba, M.; Mupapa, K.D.; Muyembe-Tamfum, J.J.; Ndaberey, E.; Peters, C.J.; Rollin, P.E.; Enden, EVD. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J. Infect. Dis., 1999, 179, S1-S7.
17. Ksiazek, T.G.; Rollin, P.E.; Williams, A.G.; Bressler, D.S.; Martin, M.L.; Swanepoel, R.; Burt, F.J.; Leman, P.A.; Khan, A.S.; Rowe, A.K.; Mukunu, R.; Sanchez, A.; Peters, C.J. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo. J. Infect. Dis., 1999, 179, S177-S187.
18. Organization, W. H. Consultation on potential Ebola therapies and vaccines. Geneva, Swizerland. http://www.who.int/mediacentre/events/meetings/2014/ebola-interventions/en/ (September 4, 2014).
19. Gupta, M.; Mahanty, S.; Ahmed, R.; Rollin, P.E. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virol., 2001, 284, 20-25.
20. Hensley, L.E.; Young, H.A.; Jahrling, P.B.; Geisbert, T.W. Proinflammatory response during Ebola virus infection of primate models: Possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett., 2002, 80, 169-179.
21. Stroher, U.; West, E.; Bugany, H.; Klenk, H.D.; Schnittler, H.J.; Feldmann, H. Infection and activation of monocytes by Marburg and Ebola viruses. J. Virol., 2001, 75, 11025-11033.
22. Geisbert, T.W.; Young, H.A.; Jahrling, P.B.; Davis, K.J.; Kagan, E.; Hensley, L.E. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: Overexpression of tissue factor in primate monocytes/macrophages is a key event. J. Infect. Dis., 2003, 188, 1618-1629.
23. Anderson, K.V. Toll signalling pathways in the innate immune response. Curr. Opin. Immunol., 2000, 12, 13-19.
24. Akira, S.; Takeda, K. Toll-like receptor signaling. Nat. Rev. Immunol., 2004, 4, 499-511.
25. Ninomiya-Tsuji, J.; Kishimoto, K.; Hiyama, A.; Inoue, J.; Cao, Z.; Matsumoto, K. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature., 1999, 398, 252-256.
26. Sato, S.; Sanjo, H.; Takeda, K.; Ninomiya-Tsuji, J.; Inoue, J.; Cao, Z.; Matsumoto K. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol., 2005, 6, 1087-1095.
27. Nishida, E.; Gotoh, Y. Trends Biochem. Sci., 1993, 18, 128.
28. Matzinger, P. An innate sense of danger. Semin Immunol., 1998, 10, 399-415.
29. Zampieri, C.A.; Fortin, J.F.; Nolan, G.P.; Nabel, G.J. The ERK Mitogen Activated Protein Kinase Pathway Contributes to Ebola Virus Glycoprotein-Induced Cytotoxicity. J Virol., 2007, 81, 1230-1240.
30. Strong, J.E.; Wong, G.; Jones, S.E.; Grolla, A.; Theriault, S.; Kobinger, G.P.; Feldmann, H. Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway. PNAS., 2008, 105, 17982-17987.
31. Halfmann, P.; Neumann, G.; and Kawaoka, Y. The Ebolavirus VP24 Protein Blocks Phosphorylation of p38 Mitogen-Activated Protein Kinase. J. Infect. Diseases., 2011, 204, S953-S956.
32. Okumura, A.; Pitha, P.M.; Yoshimura, A.; and Harty, RN. Interaction between Ebola Virus Glycoprotein and Host Toll Like Receptor 4 Leads to Induction of Proinflammatory Cytokines and SOCS1. J. Virol., 2010, 27-33.
33. Sato, M.; Suemori, H.; Hata, N.; Asagiri, M.; Ogasawara, K.; Nakao, K.; Nakaya, T.; Katsuki, M.; Noguchi, S.; Tanaka, N.; Taniguchi, T. Distinct and Essential Roles of Transcription Factors IRF 3 and IRF 7 in Response to Viruses for IFN α/β Gene Induction. Immunity., 2000, 13, 539-548.
34. Izaguirre, A.; Barnes, B.J.; Amrute, S.; Yeow, W.S.; Megjugorac, N. Comparative analysis of IRF and IFN-a expression in human plasmacytoid and monocyte-derived dendritic cells. J. Leukoc Biol., 2003, 74, 1125-1138.
35. Covert, M.W.; Leung, T.H.; Gaston, J.E.; Baltimore, D. Achieving stability of lipopolysaccharide-induced NF-kappaB activation. Sci., 2005, 309, 1854-57.
36. Kawai, T.; Adachi, O.; Ogawa, T.; Takeda, K.; Akira, S. Unresponsiveness of MyD88deficient mice to endotoxin. Immunity., 1999, 11, 115-122.
37. Xu, W.; Edwards, M.R.; Borek, D.M.; Feagins, A.R.; Mittal, A.; Alinger, J.B.; Berry, K.N.; Yen, B.; Hamilton, J.; Brett, T.J.; Pappu, R.V.; Leung, D.W.; Basler, C.F.; Amarasinghe, G.K. Ebola Virus VP24 Targets a Unique NLS Binding Site on Karyopherin Alpha 5 to Selectively Compete with Nuclear Import of Phosphorylated STAT1. Cell Host Micro., 2014, 16, 187-200.
38. Leung, D.W.; Prins, K.C.; Borek, D.M.; Farahbakhsh, M.; Tufariello, J.M.; Ramanan, P.; Nix, J.C.; Helgeson, L.A.; Otwinowski, Z.; Honzatko, R.B.; Basler, C.F.; Amarasinghe, G.K. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol., 2010, 17, 165-172.
39. Bosio, C.M.; Aman, M.J.; Grogan, C.; Hogan, R.; Ruthel, G.; Negley, D.; Mohamadzadeh, M.; Bavari, S.; Schmaljohn, A. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J. Infect. Dis., 2003, 188, 1630-1638.
40. Bell, D.; Young, J.W.; Banchereau, J. Dendritic cells. Adv. Immunol., 1999, 72, 255-324.
41. Banchereau, J.; Steinman, R.M. Dendritic cells and the control of immunity. Nature., 1998, 392, 245-252.
42. Harding, F.A.; McArthur, J.G.; Gross, J.A.; Raulet, D.H.; Allison, J.P. CD28-mediated signalling co stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature., 1992, 356, 607-609.
43. Linsley, P.S.; Brady, W.; Grosmaire, L.; Aruffo, A.; Damle, N.K.; Ledbetter, J.A. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp Med., 1991, 173, 721-730.
44. Thompson, C.B.; Lindsten, T.; Ledbetter, J.A.; Kunkel, S.L.; Young, H.A.; Emerson, S.G.; Leiden, J.M.; June, C.H. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/ cytokines. Proc. Natl. Acad. Sci. USA., 1989, 86, 1333-1337.
45. De Wit, E.; Feldmann, H.; Munster, V.J. Tackling ebola: new insights into prophylactic and therapeutic intervention strategies. Genome Med., 2011, 3, 5.
46. Geisbert, T.W.; Young, H.A.; Jahrling, P.B.; Davis, K.J.; Larsen, T.; Kagan, E. et al. Pathogenesis of Ebola hemorrhagic fever in primate models: Evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am. J. Pathol., 2003, 163, 2371-2382.
47. Mahanty, S.; Hutchinson, K.; Agarwal, S.; McRae, M.; Rollin, P.E.; Pulendran, B. Cutting edge: Impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol., 2003, 170, 2797-2801.
48. Francica, J.R.; Varela-Rohena, A.; Medvec, A.; Plesa, G.; Riley, J.L.; Bates, P. Steric Shielding of Surface Epitopes and Impaired Immune Recognition Induced by the Ebola Virus Glycoprotein. Plos Pathogens., 2010, 6, e1001098.
49. Baize, S.; Leroy, E.M.; Georges Courbot, M.C.; Capron, M.; Lansoud Soukate, J.; Debre, P.; Fisher-Hoch, S.P.; McCormick, J.B.; Georges, A.J. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med., 1999, 5, 423-426.
50. Gupta, M.; Mahanty, S.; Bray, M.; Ahmed, R.; Rollin, P.E. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J. Virol., 2001, 75, 4649-4654.
51. Parren, P.W.; Geisbert, T.W.; Maruyama, T.; Jahrling, P.B.; Burton, D.R. Pre and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J. Virol., 2002, 76, 6408-6412.
52. Takada, A.; Feldmann, H.; Stroeher, U.; Bray, M.; Watanabe, S.; Ito, H.; McGregor, M.; Kawaoka, Y. Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J. Virol., 2003, 77, 1069-1074.
53. Takada, A.; Ebihara, H.; Jones, S.; Feldmann, H.; Kawaoka, Y. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine., 2007, 25, 993-999.
54. Wilson, J.A.; Hevey, M.; Bakken, R.; Guest, S.; Bray, M.; Schmaljohn, A.L.; Hart M.K. Epitopes involved in antibody-mediated protection from Ebola virus. Sci., 2000, 287, 1664-1666.
55. Wauquier, N.; Becquart, P.; Gasquet, C.; Leroy, E.M. Immunoglobulin G in Ebola outbreak survivors, Gabon. Emerg. Infect. Dis., 2009, 15, 1136-1137.
56. Bosio, C.M.; Moore, B.D.; Warfield, K.L.; Ruthel, G.; Mohamadzadeh, M.; Aman, M.J.; Bavari, S. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virol., 2004, 326, 280-287.
57. Mahanty, S.; Hutchinson, K.; Agarwal, S., McRae, M.; Rollin, P.E.; Pulendran, B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol., 2003, 170, 2797-2801.
58. Warfield, K.L.; Perkins, J.G.; Swenson, D.L.; Deal, E.M.; Bosio, C.M.; Aman, M.J.; Yokoyama, W.M.; Young, H.A.; Bavari, S. Role of natural killer cells in innate protection against lethal Ebola virus infection. J. Exp. Med., 2004, 200, 169-179.
59. Sanchez, A.; Khan, A.S.; Zaki, S.R.; Nabel, G.J.; Ksiazek, T.G.; Peters, C.J. Filoviridae: Marburg and Ebola viruses, In: Knipe, D.M., Howley, P.M. (Eds.), Fields Virology, Four ed. Two vols., vol. One. Lippincott Williams & Wilkins, Philadelphia, pp. 1279-1304.2001.
60. Baize, S.; Leroy, E.M.; Mavoungou, E.; Fisher-Hoch, S.P. Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system? Apoptosis., 2000, 5, 5-7.
61. Mahanty, S.; Bray, M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect. Dis., 2004, 4, 487-498.
62. Sanchez, A.; Lukwiya, M.; Bausch, D.; Mahanty, S.; Sanchez, A.J.; Wagoner, K.D.; Rollin, P.E. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J. Virol., 2004, 78, 10370-10377.
63. Baize, S.; Leroy, E.M.; Georges Courbot, M.C.; Capron, M.; Lansoud Soukate, J.; Debre, P.; Fisher-Hoch, S.P.; McCormick, J.B.; Georges, A.J. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med., 1999, 5, 423-426.
64. Gupta, M.; Spiropoulou, C.; Rollin, P.E. Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub-populations in vitro. Virol., 2007, 364, 45-54.
65. Hoenen, T.; Groseth, A.; Feldmann, H. Current ebola vaccines. Expt. Opinion. Biol. therap., 2012, 12, 859-872.
66. Feldmann, H.; Jones, S.M.; Daddario-DiCaprio, K.M.; Geisbert, J.B.; Stroher, U.; Grolla, A.; Bray, M.; Fritz, E.A.; Fernando, L.; Feldmann, F.; Hensley, L.E.; Geisbert, T.W. Effective Post-Exposure Treatment of Ebola Infection. PLoS Pathogens., 2007, 3, e2.
67. Geisbert, T.W.; Daddario-DiCaprio, K.M.; Williams, K.J.; Geisbert, J.B.; Leung, A.; Feldmann, F.; Hensley, L.E.; Feldmann, H.; Jones, S.M. Recombinant Vesicular Stomatitis Virus Vector Mediates Postexposure Protection against Sudan Ebola Hemorrhagic Fever in Nonhuman Primates. Virol., 2008, 82, 5664-5668.
68. Bausch, D.G.; Feldmann, H.; Geisbert, T.W.; Bray, M.; Sprecher, A.G.; Boumandouki, P.; Rollin, P.E.; Roth, C. Outbreaks of Filovirus Hemorrhagic Fever: Time to Refocus on the Patient. J. Infect. Diseases., 2007, 196, S136-S141.
69. Jeffs, B. A clinical guide to viral haemorrhagic fevers: Ebola, Marburg and Lassa”. Tropical Doctor. 2006, 36, 1-4.
70. Kaushik, A.; Tiwari, S.; Jayant, R.D.; Marty, A.; Nair, M. Towards detection and diagnosis of Ebola virus disease at point-of-care. Biosensors and Bioelectronics., 2016, 75, 254-272.
71. Pollack, Andrew (7 August 2014) Second Drug Is Allowed for Treatment of Ebola The New York Times, Retrieved 2014-08-08.
72. Feldmann, H.; Geisbert, T.W. Ebola haemorrhagic fever. Lancet., 2011, 377, 849-862.
73. Geisbert, T.W.; Hensley, L.E.; Jahrling, B.P.; Larsen, T.; Geisbert, J.B.; Paragas, J.; Young, H.A.; Fredeking, T.M.; Rote, W.E.; Vlasuk, G. P. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet., 2003, 362, 1953-1958.
74. Remick, D.G.; Kunkel, R.G.; Larrick, J.W.; Kunkel, S.L. Lab. Invest., 1987, 56, 583-90.
75. Esmon, C.T.; Pract, B.B. Clin Haemotol., 1999, 12, 343-59.
76. Little, M.A.; Bhangal, G.; Smyth, C.L.; Nakada, M.T.; Cook, H.T.; Nourshargh Pusey, C.D. Therapeutic Effect of Anti-TNF-Antibodies in an Experimental Model of Anti-Neutrophil Cytoplasm Antibody Associated Systemic Vasculitis. J. Am.Soc.Nephrol., 2006, 1, 160-169.
77. Sanchez, A.; Lukwiya, M.; Bausch, D.; Mahanry, S.; Sanchez, A.J.; Wagoner, K.D.; Rollin, P. E. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J. Virol., 2004, 78, 10370-10377.
78. Gupta, M.; Mahanty, S.; Ahmed, R.; Rollin, P.E. J.Virol., 2001, 284, 20-25.
79. Baize, S.; Leroy, E.M.; Georges, A.; Georges Courbot, M.C.; Capron, M.; Bedjabaga, I.; Lansoud-Soukate, I.; Mavoungou, E. Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immllnol., 2002, 128, 163-168.
80. Hensley, L.E.; Young, H.A.; Jahrling, P.B.; Geisbert, T.W. Immunol. Lett., 2002, 80, 169-179.
81. Rubins, K.H, Hensley, L.E.; Wahl Jensen, V.; DaddarioDicaprio, K.M.; Young, H.A.; Reed, D.; Jahrling, P.B.; Brown, P.O.; Reiman, D.A.; Geisbert, T.W. Genome BioI., 2007, 8, R174.
82. Talavera, J.; Castillo, D.; Dominguez, A.M.; Gutierrez, M.C.; Meza, A.E.; Gen, I. J.Virol., 2004, 85, 1801-1813.
83. Sergeev, A.N.; Ryzhikov, A.B.; Bulychev, L.E.; Evtin, N.K.; P'lankov, V.; P'lankova, G.; Slezkina, E.I.; Kotliarov, L.A.; Petrishchenko, V.A.; Pliasunov, V. Vopr.Virusol., 1997, 42, 226-229.
84. Bray, M.; Raymond, JL.; Geisbert, T.; Baker, OR. 3-Deazaneplanocin A induces massively increased interferon-α production in Ebola virus-infected mice. Antiviral Res., 2002, 55, 151-159.
85. Peters, C.J.; Le Duc, W. J. Infect. Dis., 1999, 179(Suppll), p. ixxvi.
86. Oestereicha, L.; Ludtke, A.; Wurr, S.; Rieger, T.; Munoz-Fontela, C.; Gunther, S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res., 2014, 105, 17-21.
87. Feldmann, H.; Geisbert, T.W. Ebola haemorrhagic fever. Lancet., 2011, 377, 849-862.
88. Warren, T.K.; Warfield, K.L.; Wells, J.; Swenson, D.L.; Donner, K.S.; Tongeren, S.A.V.; Garza, N.L.; Dong, L.; Mourich, D.V.; Crumley, S.; Nichols, D.K.; Iversen, P.L.; Bavari, S. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat. Med., 2010, 16, 991-994.
89. Singh Jadav, S.; Kumar, A.; Jawed Ahsan, M.; Jayaprakash, V. Ebola Virus: Current and Future Perspectives. Infect. Disorders-Drug Targets, 2015, 15, 20-31.
90. Kondratowicz, A.S.; Lennemann, N.J.; Sinn, P.L.; Davey, R.A.; Hunt, C.L.; Moller-Tank, S.; Meyerholz, D.K.; Rennert, P.; Mullins, R.F.; Brindley, M.; Sandersfeld, L.M.; Quinn, K.; Weller, M.; McCray, P.B.; Chiorini, J.; Maury, W. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc. Natl Acad. Sci. USA, 2011, 108, 8426-8431.
91. Miller, E.H.; Harrison, J.S.; Radoshitzky, S.R. Miller, Higgins, C.D.; Chi, X.; Dong, L.; Kuhn, J.H.; Bavari, S.; Lai, J.R.; Chandran, K. Inhibition of Ebola virus entry by a C-peptide targeted to endosomes. J. Biol. Chem., 2011, 286, 15854-15861.
92. Wolf, M.C.; Freiberg, A.N.; Zhang, T.; Akyol-Ataman, Z.; Grock, A.; Hong, P.W.; Li, J.; Watson, N.F.; Fang, A.Q.; Aguilar, H.C.; Porotto, M.; Honko, A.N.; Damoiseaux, R.; Miller, J.P.; Woodson, S.E.; Chantasirivisal, S.; Fontanes, V.; Negrete, O.A.; Krogstad, P.; Dasgupta, D.; Moscona, A.; Hensley, L.E.; Whelan, S.P.; Faull, K.F.; Holbrook, M.R.; Jung, M.E.; Lee, B. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Nat. Acad. Sci. USA., 2010, 107, 3157-3162.
93. Kinch, M.S.; Yunus, A.S.; Lear, C.; Mao, H.; Chen, H.; Fesseha, Z.; Luo, G.; Nelson, E.A.; Li, L.; Huang, Z.; Murray, M.; Ellis, W.Y.; Hensley, L.; Hennings, J.C.; Olinger, G.G.; Goldblatt M. FGI-104: a broadspectrum small molecule inhibitor of viral infection. Am. J. Transl. Res., 2009, 1, 87-98.
94. Aman, M.J.; Kinch, M.S.; Warfield, K.; Warren, T.; Yunus, A.; Enterlein, S.; Stavale, E.; Wang, P.; Chang, S.; Tang, Q.; Porter, K.; Goldblatt, M.; Bavari, S. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res., 2009, 83, 245-251.
95. Warren, T.K.; Warfield, K.L.; Wells, J.; Enterlein, S.; Smith, M.; Ruthel, G.; Yunus, A.S.; Kinch, M.S.; Goldblatt, M.; Aman M.J.; Bavari, S. Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob. Agents. Chemother., 2010, 54, 2152-2159.
96. Aman, M.J.; Kinch, M.S.; Warfield, K.; Warren, T.; Enterlein, S.; Stavale, E.; Wang, P.; Chang, S.; Yunus, A.; Tang, Q.; Porter, K.; Goldblatt, M.; Bavari, S. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral. Res., 2009, 83, 245-251.
97. Connor, J.H.; McKenzie, M.O.; Parks, G.D.; Lyles, D.S. Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses. Virol., 2007, 362, 109-119.
98. Smith, D.R.; McCarthy, S.; Chrovian, A.; Olinger, G.; Thomas, S.A.; Geisbert, W.; Hensley, L.E.; Connor, J.H. Antiviral Res., 2010, 87, 187-194.
99. Hart, M.K. Vaccine research efforts for filoviruses. Int. J. Parasitol., 2003, 33, 583-595.
100. Nabel, G.J. Vaccine for AIDS and Ebola virus infection. Virus Res., 2003, 92, 213-217.
101. Ji, X.; Olinger, G.G.; Aris, S.; Chen, Y.; Gewurz, H.; Spear, G.T. Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J. Gen. Virol., 2005, 86, 2535-2542.
102. Michelow, IC.; Lear, C.; Scully, C.; Prugar, L.I., Clifford B. Longley, Matthew Brudner, L. Michael Yantosca, Kazue Takahashi, Xin Ji, Marshall Karpel, Gregory T. Spear, R. Alan, B. Ezekowitz, Emmett V. Schmidt, and Gene G. Olinger. High-Dose Mannose-Binding Lectin Therapy for Ebola Virus Infection. The J.Infect. Diseases, 2011, 203, 175-179.
103. Michelow, I.; Olinger, G.; Spear, G.; Yantosca, L.; Ji, X.; Takahashi, K.; Schmidt, E. Control of Ebola virus infection in mice with recombinant human mannosebinding lectin: Requirement for C3. Mol. Immunol., 2008, 8, 205.
104. Bosio, C.M.; Moore, B.D.; Warfield, K.L.; Ruthel, G.; Mohamadzadeh, M.; Aman, M.J.; Bavari, S. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virol., 2004, 326, 280-287.
105. Ye, L.; Lin, J.; Sun, Y.; Bennouna, S.; Lo, M.; Wu, Q.; Bu, Z.; Pulendran, B.; Compans, R.W.; Yang, C. Ebola virus like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virol., 2006, 351, 260-270.
106. Martinez, O.; Valmas, C.; Basler, C.F. Ebola viruslike particle-induced activation of NF-κB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain. Virol., 2007, 364, 342-354.
107. Harty, J.T.; Tvinnereim, A.R.; White, D.W. CD8 + T cell effector mechanisms in resistance to infection. Annu. Rev. Immunol., 2000, 18:275.
108. Binder, G.K.; Griffin, D.E. Interferonγ-mediated sitespecific clearance of alpha virus from CNS neurons. Sci., 2001, 293, 303.
109. Wilson, J.A.; Hart, M.K. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J. Virol., 2001, 75, 2660.
110. Gupta, M.; Mahanty, S.; Greer, P.; Towner, J.S.; Shieh, W.J.; Zaki, S.R.; Ahmed, R.; Rollin, P.E. Persistent infection with Ebola virus under conditions of partial immunity. J. Virol., 2004, 78, 958.
111. Gupta, M.; Ahmed, R.; Greer, P.; Mahanty, S.; Shieh, W.J.; Zaki, S.R, Rollin, P.E. CD8-Mediated Protection against Ebola virus infection is Perforin dependent. J. Immunol., 2005, 174, 4198-4202.
112. Feldmann, H.; Sanchez, A, Klenk HD. Filoviruses. In: Collier HD, editor. Topley and Wilson’s microbiology and microbial infections. 9th ed. London: Edward Arnold; 1998, pp. 651-64.
113. Sanchez, A.; Khan, A.S.; Zaki, S.R.; Nabel, G.J.; Ksiazek, TG.; Peters, C.J. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, editors. Fields virology. 4th ed. Lippincott-Williams & Wilkins: Philadelphia; 2001, 1279-304.
114. Wool-Lewis, R.J.; Bates, P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J. Virol., 1998, 72, 3155-60.
115. Volchkov, V.E.; Becker, S.; Volchkova, V.A.; Ternovoj, V.A.; Kotov, A.N.; Netesov SV, Dieter klenk, H. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virol., 1995, 214, 421-30.
116. Takada, A.; Feldmann, H.; Stroeher, U.; Bray, M.; Watanabe, S.; Ito, H.; McGregor, M.; Kawaoka, Y. Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level using recombinant vesicular stomatitis viruses. Virol., 2003, 77, 1069-74.
117. Wilson, J.A.; Hevey, M.; Bakken, R.; Guest, S.; Bray, M.; Schmaljohn, A.L.; Hart, M.K. Epitopes involved in antibody-mediated protection from Ebola virus. Sci., 2000, 287, 1664-1666.
118. Sullivan, N.J.; Martin, J.E.; Graham, B.S.; Nabel, G.J. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol., 2009, 7, 393-400.
119. Shedlock, D.J., Bailey, M.A., Popernack, P.M., Cunningham, J.M.; Burton, D.R.; Sullivan, N. J. Virol., 2010, 401, 228-235.
120. Wang, Y.; Liu, Z.; Dai, Q.A. Highly immunogenic fragment derived from Zaire Ebola virus glycoprotein elicits effective neutralizing antibody. Virus. Res., 2014, 189, 254-261.